Results 241 to 250 of about 87,055 (290)
Some of the next articles are maybe not open access.

The application of PROTAC in HDAC

European Journal of Medicinal Chemistry, 2023
Inducing protein degradation by proteolysis targeting chimera (PROTAC) has provided great opportunities for scientific research and industrial applications. Histone deacetylase (HDAC)-PROTAC has been widely developed since the first report of its ability to induce the degradation of SIRT2 in 2017.
Shaoting Chen   +7 more
openaire   +2 more sources

Inside HDACs with more selective HDAC inhibitors

European Journal of Medicinal Chemistry, 2016
Inhibitors of histone deacetylases (HDACs) are nowadays part of the therapeutic arsenal mainly against cancers, with four compounds approved by the Food and Drug Administration. During the last five years, several groups have made continuous efforts to improve this class of compounds, designing more selective compounds or compounds with multiple ...
Roche, Joëlle, Bertrand, Philippe
openaire   +2 more sources

HDAC Inhibitors

2016
Lysine acetylation in proteins is one of the most abundant posttranslational modifications in eukaryotic cells. The dynamic homeostasis of lysine acetylation and deacetylation is dictated by the action of histone acetyltransferases (HAT) and histone deacetylases (HDAC).
Heidi, Olzscha   +3 more
openaire   +2 more sources

HDAC inhibitors in HIV

Immunology & Cell Biology, 2011
Combination antiretroviral therapy (cART) has led to a very substantial reduction in morbidity and mortality in HIV‐infected patients; however, cART alone is unable to cure HIV and therapy is lifelong. Therefore, a new strategy to cure HIV is urgently needed.
Wightman, F   +3 more
openaire   +3 more sources

HDACs and HDAC Inhibitors in Urothelial Carcinoma – Perspectives for an Antineoplastic Treatment

Current Medicinal Chemistry, 2017
Histone deacetylases (HDACs) influence diverse cellular processes and may contribute to tumor development and progression by multiple mechanisms. Class I HDACs are often overexpressed in cancers contributing to a genome-wide epigenetic state permitting increased proliferation, and diminished apoptosis and cell differentiation.
Maria, Pinkerneil   +3 more
openaire   +2 more sources

Choosing pan-HDAC or selective HDAC inhibitors for anticancer therapy

Drug Discovery Today
Dysfunction of histone deacetylases (HDACs) is linked to oncogenesis and progression. The expression of classical HDACs varies across different cancers. In some cancers, isozymes of one HDAC class are overactive, whereas in others, multiple classes are involved.
Shabir Ahmad Ganai   +2 more
openaire   +2 more sources

Teratogenic Activity of HDAC Inhibitors

Current Pharmaceutical Design, 2014
Modification of the terminal tails of histones is considered one of the documented mechanisms for epigenetic control of gene expression. Histone deacetylase inhibitors (HDACi) lead to a state of hyperacetylation of histone, a condition that can affect normal gene transcription.
E. Giavini, E. Menegola
openaire   +2 more sources

HATs and HDACs

2007
DNA in eukaryotes is arranged into higher order structures termed chromatin. Chromatin poses an obstacle for gene transcription because it is not readily accessible to DNA binding transcription factors. Chromatin also provides the structural basis for gene regulation, keeping most genes in a default state of repression.
Timothy A. Bolger   +2 more
openaire   +1 more source

The Clinical Landscape of HDAC Inhibitors

Medical Epigenetics, 2021
Arasu Ganesan
exaly  

Home - About - Disclaimer - Privacy